Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 22, 2021 - Issue 2
Submit an article Journal homepage
582
Views
2
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Evaluation of cardiovascular and renal outcomes with ertugliflozin: what is the VERdict from the VERTIS-CV trial?

Kevin Cowarta Department of Pharmacotherapeutics & Clinical Research, Taneja College of Pharmacy, Tampa, FL, USA;b Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6880-1600View further author information
ORCID Icon &
Nicholas W. Carrisa Department of Pharmacotherapeutics & Clinical Research, Taneja College of Pharmacy, Tampa, FL, USA;c Department of Family Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USAView further author information
Pages 163-165 | Received 16 Jul 2020, Accepted 08 Sep 2020, Published online: 23 Sep 2020

References

  • Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial - VERTIS CV. Presented by Dr. Christopher P. Cannon at the American Diabetes Association Virtual Scientific Sessions J. 2020. [Cited 2020 Jul 14]. Available from: https://www.acc.org/latest-in-cardiology/clinical-trials/2020/06/16/11/24/vertis#references-for-article
  • Cannon CP, McGuire DK, Pratley R, et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety cardiovascular outcomes trial (VERTIS-CV). Am Heart J. 2018;206:11–23.
  • Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
  • Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
  • Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
  • Kaku K, Lee J, Mattheus M, et al. Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular disease - results from EMPA-REG OUTCOME(®). Circ J. 2017;81(2):227–234.
  • Kyriakos G, Quiles-Sanchez LV, Garmpi A, et al. SGLT2 inhibitors and cardiovascular outcomes: do they differ or there is a class effect? New insights from the EMPA-REG OUTCOME trial and the CVD-REAL study. Curr Cardiol Rev. 2019;10.2174/1573403X15666190730094215. DOI:10.2174/1573403X15666190730094215.
  • Kenny Helena C, Abel ED. Heart failure in type 2 diabetes mellitus. Circ Res. 2019;124(1):121–141.
  • Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306.
  • Cherney DZI, Heerspink HJL, Frederich R, et al. Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials. Diabetologia. 2020;63(6):1128–1140.
  • Kluger AY, Tecson KM, Lee AY, et al. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc Diabetol. 2019;18(1):99.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.